NCT01257386View on ClinicalTrials.gov

Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis

PHASE3CompletedINTERVENTIONAL

Enrollment

251

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

August 31, 2012

Study Completion Date

March 31, 2013

Conditions

Active Ulcerative Colitis

Interventions

DRUG

Asacol®

400mg tablets

DRUG

Mesalazine

400mg tablets

Trial Locations (1)

Unknown

Shanghai Hospital, Shanghai

Sponsors

Collaborators (1)

Zeria Pharmaceutical

All Listed Sponsors

collaborator

Zeria Pharmaceutical

INDUSTRY

lead

Tillotts Pharma AG

INDUSTRY